Fate Therapeutics
FATEAlgoritmens signaler
- ›Starkt 3m-momentum (+96.0%)
- ›Starkt 6m-momentum (+105.9%)
- ›Starkt 12m-momentum (+131.1%)
- ›Pris över MA50 och MA200 (uppåttrend)
- ›Hög volatilitet (104% årlig)
- ›+169% från 52v-botten
📰 Senaste nyheter & analys
Källor: Placera, Nyhetsbyrån Direkt, Google NewsFate Therapeutics, Inc. Revenue Breakdown – NASDAQ:FATE - TradingView
2026-07-25Fate Therapeutics, Inc. Revenue Breakdown – NASDAQ:FATE TradingView
TradingViewFATE News | FATE THERAPEUTICS INC (NASDAQ:FATE) - ChartMill
2026-07-18FATE News | FATE THERAPEUTICS INC (NASDAQ:FATE) ChartMill
ChartMillFate Therapeutics Receives FDA Clearance of Investigational New Drug Application for FT839 Product Candidate - GlobeNewswire
2026-07-09Fate Therapeutics Receives FDA Clearance of Investigational New Drug Application for FT839 Product Candidate GlobeNewswire
GlobeNewswireFate Therapeutics Insiders Benefit From Selling Stock At US$1.54 - simplywall.st
2026-07-06Fate Therapeutics Insiders Benefit From Selling Stock At US$1.54 simplywall.st
simplywall.stFate Therapeutics Stock Pops As FT836 Cancer Data Impress Traders - StocksToTrade
2026-06-28Fate Therapeutics Stock Pops As FT836 Cancer Data Impress Traders StocksToTrade
StocksToTradeFate Therapeutics’s FT819 Progress Keeps My Bull Case Alive (NASDAQ:FATE) - Seeking Alpha
2026-06-24Fate Therapeutics’s FT819 Progress Keeps My Bull Case Alive (NASDAQ:FATE) Seeking Alpha
Seeking AlphaWill Fate Therapeutics (NASDAQ:FATE) Spend Its Cash Wisely? - Yahoo Finance
2026-05-30Will Fate Therapeutics (NASDAQ:FATE) Spend Its Cash Wisely? Yahoo Finance
Yahoo FinanceJefferies initiates Fate Therapeutics stock with buy rating on autoimmune potential - Investing.com
2026-05-19Jefferies initiates Fate Therapeutics stock with buy rating on autoimmune potential Investing.com
Investing.comFATE SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Fate Therapeutics, Inc. (NASDAQ: FATE) and Encourages Long-Term FATE Investors to Contact the Firm
2024-06-13FATE SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Fate Therapeutics, Inc. (NASDAQ: FATE) and Encourages Long-Term FATE Investors to Contact the Firm PR Newswire PHILADELPHIA, June 13,
Fate TherapeuticsPR NewswireFATE THERAPEUTICS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Fate Therapeutics, Inc. - FATE
2023-07-01Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Fate Therapeutics,
Fate TherapeuticsBusiness WireFATE THERAPEUTICS ALERT: Bragar Eagel & Squire, P.C. is Investigating Fate Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
2023-06-22Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Fate Therapeutics, Inc. (NASDAQ: FATE) on behalf of long-term stockholders f
Fate TherapeuticsBusiness WireFate ALERT: Bragar Eagel & Squire, P.C. is Investigating Fate Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
2023-06-09Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Fate Therapeutics, Inc. (NASDAQ: FATE) on behalf of long-term stockholders f
Fate TherapeuticsBusiness WireFINAL DEADLINE TODAY: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Fate Therapeutics, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important March 22 Deadline in Securities Class Action – FATE
2023-03-22WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Fate Therapeutics, Inc. (NASDAQ: FATE) between April 2, 2020 and January 5, 2023, both dates inclusive (
Fate Therapeutics IncBusiness WireSHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Fate Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of March 22, 2023 - (NASDAQ: FATE)
2023-03-22SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Fate Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of March 22, 2023 - (NASDAQ: FATE) PR Newswire NEW YORK,
Fate TherapeuticsPR NewswireFATE DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Fate Therapeutics, Inc. and Encourages Investors to Contact the Firm
2023-03-22Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against Fate Therapeutics, Inc. (“Fate” or the “Company”)
Fate Therapeutics IncBusiness WireThe Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Fate Therapeutics, Inc. (FATE)
2023-03-21The Law Offices of Frank R. Cruz reminds investors of the upcoming March 22, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Fate Therapeuti
Fate Therapeutics IncBusiness Wire
Klicket på "Köp i Nordnet" öppnar din Nordnet-app om installerad — där loggar du in med BankID. Annars öppnas Nordnets webbsajt där du kan logga in med BankID på samma sätt.